ArticleScientific reports2026
Evaluation of dECM hydrogel-NAP on 3D organotypic human corneal epithelium in diabetic keratopathy model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Diabetes mellitus, a global epidemic, is a leading cause of blindness due to its detrimental effects on the retina, lens, and cornea. Diabetic keratopathy (DK), a significant ocular complication, severely compromises the corneal epithelium structure, barrier function, and healing capacity, largely driven by hyperglycemia-induced oxidative stress and apoptosis. Current therapeutic strategies for DK are limited and primarily symptomatic, failing to address underlying cellular deficits. This study investigates a novel regenerative approach utilizing a decellularized extracellular matrix (dECM) hydrogel functionalized with the neuroprotective peptide NAP (dECM hydrogel-NAP). Both dECM hydrogels and NAP have demonstrated promising regenerative and protective properties in various tissues, though their combined efficacy for diabetic corneal repair remains unexplored. Using a three-dimensional (3D) organotypic human corneal epithelium model of DK, we evaluated the therapeutic potential of dECM hydrogel-NAP to promote epithelial wound healing, restore barrier function, mitigate apoptotic responses, and support cellular viability under diabetic conditions. Our findings suggest that dECM hydrogel-NAP holds significant promise as a therapeutic strategy for supporting corneal epithelial regeneration in diabetic keratopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.